This study examined the possible hypoglycemic effects Angelica gigas Naki extracts in streptozotocin-induced diabetic rats(STZ+50%, STZ+100% EtOH and STZ+water). The studies showed that administration of the Angelica gigas Naki extract decreased high blood glucose levels(more than 300 mg/$d{ell}$) to a normal level(104 mg/$d{ell}$) in the STZ+50% EtOH group. Liver glucokinase levels were significantly increased in STZ+50% EtOH and STZ+100% EtOH groups compared to the STZ group. Moreover, the liver acetyl CoA carboxylase level was significantly increased in STZ+50% EtOH, STZ+100% EtOH and STZ+water groups compared to the STZ group. These results suggest that the Angelica gigas Naki extract in the STZ+50% EtOH group exerted an ameliorable effect and can be used as an anti-diabetic substance, either as a dietary supplements or as a new drug.